Contralateral second breast cancers: Prediction and prevention

Journal of the National Cancer Institute

Volumn 102, Issue 7, 2010, Pages 444-445

  Brenner, David J ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; ATM PROTEIN; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; TP53 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; EDITORIAL; GENE MUTATION; GENETIC RISK; HUMAN; PRIORITY JOURNAL; SECOND CANCER; BREAST TUMOR; DNA DAMAGE; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC PREDISPOSITION; GENETICS; MUTATION; NOTE; RADIATION EXPOSURE; RADIATION INDUCED NEOPLASM; RADIATION INJURY; RISK ASSESSMENT; RISK FACTOR;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; CELL CYCLE PROTEINS; DNA DAMAGE; DNA-BINDING PROTEINS; ENVIRONMENTAL EXPOSURE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; PROTEIN-SERINE-THREONINE KINASES; RADIATION INJURIES; RISK ASSESSMENT; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 77950568598     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq058     Document Type: Editorial

References (22)

1. American Cancer Society. Breast Cancer Facts & Figures 2009-2010. Atlanta, GA: American Cancer Society, Inc; 2009.
2. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717. (Pubitemid 40719106)
3. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087-2106. (Pubitemid 41797643)
4. Freedman GM, Anderson PR, Hanlon AL, Eisenberg DF, Nicolaou N. Pattern of local recurrence after conservative surgery and whole-breast irradiation. Int J Radiat Oncol Biol Phys. 2005;61(5):1328-1336. (Pubitemid 40470412)
5. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56(4):1038-1045. (Pubitemid 36794035)
6. Bertelsen L, Bernstein L, Olsen JH, et al. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2008;100(1):32-40. (Pubitemid 351767339)
7. Saur S, Fjellsboe LM, Lindmo T, Frengen J. Contralateral breast doses measured by film dosimetry: tangential techniques and an optimized IMRT technique. Phys Med Biol. 2009;54(15):4743-4758.
8. Brenner DJ, Shuryak I, Russo S, Sachs RK. Reducing second breast cancers: a potential role for prophylactic mammary irradiation. J Clin Oncol. 2007;25(31):4868-4872. (Pubitemid 350220415)
9. Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med. 1992;326(12):781-785.
10. Berrington de Gonzalez A, Curtis RE, Gilbert E, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer. 2010;102(1):220-226.
11. Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst. 1995;87(22):1681-1685.
12. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31(1):33-36.
13. Graeser MK, Engel C, Rhiem K, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009;27(35):5887-5892.
14. Bernstein JL, Haile RW, Stovall M, et al. Radiation exposure, the ATM gene, and contralateral breast cancer in the Women's Environmental Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2010;102(7):475-483.
15. Concannon P, Haile RW, Borresen-Dale AL, et al. Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. Cancer Res. 2008;68(16):6486-6491.
16. Broeks A, Braaf LM, Huseinovic A, et al. The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat. 2008;107(2):243-248. (Pubitemid 350265692)
17. Shafman TD, Levitz S, Nixon AJ, et al. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer. 2000;27(2):124-129. (Pubitemid 30030309)
18. Baynes C, Healey CS, Pooley KA, et al. Common variants in the ATM, "RCA1, "RCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res. 2007;9(2):R27. (Pubitemid 350215160)
19. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997;89(22):1673-1682. (Pubitemid 27508191)
20. Alkner S, Bendahl PO, Ferno M, Nordenskjold B, Ryden L. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: results from a controlled randomised trial. Eur J Cancer. 2009;45(14):2496-2502.
21. Vitolo U, Ferreri AJ, Zucca E. Primary testicular lymphoma. Crit Rev Oncol Hematol. 2008;65(2):183-189.
22. Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20-27